Eptifibatide (Integrilin)

Cyclic peptide that acts as a platelet glycoprotein IIB-IIIA antagonist, reversibly inhibiting the binding of FIBRINOGEN; VON WILLEBRAND FACTOR; and other adhesive molecules to the GPIIB-IIIA RECEPTORS of platelets. It is used in the management of UNSTABLE ANGINA and in patients undergoing coronary ANGIOPLASTY and stenting procedures.

Also Known As:

Networked: 562 relevant articles (79 outcomes, 193 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Harrington, Robert A: 34 articles (04/2017 - 07/2001)
2.	Califf, Robert M: 24 articles (04/2014 - 07/2001)
3.	Gibson, C Michael: 21 articles (04/2014 - 04/2003)
4.	Califf, R M: 20 articles (07/2002 - 01/2000)
5.	Giugliano, Robert P: 19 articles (04/2017 - 04/2003)
6.	Armstrong, Paul W: 19 articles (04/2014 - 01/2002)
7.	Harrington, R A: 19 articles (07/2002 - 01/2000)
8.	Topol, E J: 19 articles (02/2002 - 01/2000)
9.	Newby, L Kristin: 18 articles (04/2014 - 06/2003)
10.	Lincoff, A M: 14 articles (07/2002 - 02/2000)

Related Diseases

1.	Acute Coronary Syndrome 09/01/2013 - "Consistent with previous literature, upstream treatment with eptifibatide was associated with improved outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients treated with PCI; however, a nonsignificant interaction term precludes a definite conclusion." 11/01/2007 - "The alphaIIbbeta3 antagonist eptifibatide is an effective treatment for patients with acute coronary syndromes (ACS). " 09/01/2000 - "PURSUIT was a double-blind, randomized trial that examined the efficacy of eptifibatide (180 microg/kg bolus + continuous infusion of 2.0 microg/kg/min for < or =96 h) versus placebo among patients who had acute coronary syndromes but not persistent ST-segment elevation. " 11/01/2011 - "Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function." 12/01/1998 - "Efficacy of eptifibatide in patients with acute coronary syndromes."
2.	Myocardial Infarction 12/01/2004 - "The PURSUIT trial provided evidence that eptifibatide decreases death or non-fatal myocardial infarction (MI) in the main group and in the diabetic subgroup. " 01/01/2004 - "In this study, the primary combined endpoint (composite of death, myocardial infarction [MI] or target vessel revascularization [TVR] at 30 days) occurred in 9.6% of the patients assigned to eptifibatide bolus followed by the 4-hour infusion versus 12.2% in the placebo group (p = 0.67). " 09/01/2013 - "After multivariable adjustment, compared with delayed provisional use, routine early eptifibatide was associated with lower rate of 30-day death or myocardial infarction (MI) after PCI (hazard ratio [HR] 0.80, 95% CI 0.68-0.95) but not with medical management (HR 0.97, 95% CI 0.74-1.29); PCI × randomized treatment interaction term P = .24. " 01/01/2012 - "Microvascular effect of intracoronary eptifibatide in acute myocardial infarction." 01/01/2011 - "Despite a Thrombolysis in Myocardial Infarction risk score of only 2, she was also given eptifibatide infusion because of clinical concerns. "
3.	ST Elevation Myocardial Infarction 01/01/2016 - "IC administration of eptifibatide during PPCI in patients with STEMI in comparison with IV administration of eptifibatide is associated with significantly better coronary reperfusion and improved clinical outcomes (IRCT2012090510751N1)." 08/01/2011 - "The adjunctive use of eptifibatide in patients presenting with STEMI may be associated with improved clinical outcomes. " 06/01/2007 - "In patients with ST-segment elevation myocardial infarction (STEMI), eptifibatide has been studied as adjunct to primary PCI and improved epicardial flow and tissue reperfusion. " 01/01/2007 - "In patients with STEMI eptifibatide has been studied as an adjunct to fibrinolysis and primary PCI; it improved epicardial flow and tissue reperfusion. " 04/15/2023 - "Therefore, in this study, we investigated the effect of maintenance dose of Eptifibatide in patients with STEMI who underwent PPCI. "
4.	Unstable Angina 03/01/1999 - "Eptifibatide is also beneficial in patients undergoing PCI, whether or not they have unstable angina or non-Q-wave MI. " 11/01/1996 - "To test this hypothesis, we investigated retrospectively the results of a trial on Integrelin in unstable angina. " 01/01/2002 - "The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy." 12/01/2000 - "Early use of eptifibatide prior to coronary artery bypass graft surgery in a patient with unstable angina." 04/15/1999 - "Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy."
5.	Hemorrhage 09/10/2013 - "The amount by which TIMI major bleeding was increased with early vs. delayed provisional eptifibatide use was significantly greater with increasing age (p interaction=0.02), but the age×treatment interactions were not significant for GUSTO moderate/severe bleeding or transfusion (p interaction=0.33 and 0.54, respectively). " 07/01/2019 - "Eptifibatide has increased the risk of bleeding complications, although it is effective in reducing mortality and morbidity. " 07/01/2019 - "Eptifibatide is routinely used in bolus and infusion forms and the aim of this study is to evaluate the efficacy of bolus-only dose and bolus + infusion strategy for administrating eptifibatide in bleeding complications and consequences after PCI. " 07/01/2019 - "The results of this study suggested that bolus-only dose of eptifibatide before PCI could be able to decrease significantly bleeding complication and other clinical and cardiovascular outcomes." 12/01/2009 - "The study aimed to determine the impact on eptifibatide-associated bleeding by implementing a computerized dosing algorithm in the cardiac catheterization suite. "

Related Drugs and Biologics

1.	Eptifibatide (Integrilin)
2.	Tirofiban (Aggrastat)
3.	Aspirin (Acetylsalicylic Acid)
4.	Platelet Membrane Glycoproteins
5.	Abciximab (ReoPro)
6.	Glycoproteins (Glycoprotein)
7.	Heparin (Liquaemin)
8.	Enoxaparin (Lovenox)
9.	Platelet Membrane Glycoprotein IIb
10.	Clopidogrel (Plavix)

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Therapeutics
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Stents
5.	Drug-Eluting Stents